You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Measuring toxicant effects on cellular function in a microarray format
SBC: CIENCIA INC Topic: 113Project Summary/Abstract – The EPA maintains a Toxics Release Inventory of andgt;650 toxic chemicals that are disposed or released from andgt;20,000 industrial sites in the United States, while HHS and USDA maintain a list of over 60 select agents and toxicants that pose a severe risk to human, animal, and plant health. These compounds represent only a fraction of the known and unknown environme ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Infant NeuroLUX: A Novel Non-invasive Therapeutic Device for Neonatal Hypoxic Brain Injury
SBC: Mitovation, Inc. Topic: 101Neonatal hypoxia/ischemia is a known cause of cerebral damage resulting from inadequate blood flow and/or oxygen delivery to the infant brain before, during, or after birth. The occurrence among hospital deliveries is ~2-4 per 1000 full-term births with a drastic increase among premature newborns. The deficit in oxygen delivery to the brain results in extensive damage and severe disabilities. Rest ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting glioblastoma stem-like cells with custom-designed viral vectors
SBC: Lacerta Therapeutics, Inc. Topic: 102Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
The Sustainable Heartland Accelerator Regional Partnership (SHARP) Hub
SBC: BBC ENTREPRENEURIAL TRAINING & CONSULTING LLC Topic: 500Project Summary/Abstract Despite the investment of billions of dollars in biomedical research each year from NIH, barriers remain in effectively translating basic science discoveries from academia to commercial products that benefit patients. These barriers include a funding gap between basic research and commercial developments, a lack of knowledge by innovators on how to bring products to market ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome
SBC: Longeveron LLC Topic: NIAThe metabolic syndrome (MetS) is a cluster of factors that increases the risks for cardiovascular disease, type 2 diabetes mellitus, and mortality, and currently affects andgt; 40% of US adults. MetS is associated with endothelial dysfunction, decreased circulating endothelial progenitor cells (EPCs), and a pro-inflammatory state. We have made the exciting discovery that therapy with allogeneic me ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Production and Characterization of Human Immunoglobulin Producing Goats for Diagnostic Reagents and Therapeutics
SBC: SAB CAPRA, LLC Topic: NIAIDProject Summary/Abstract The ultimate goal of this phase II STTR proposal is to expand the capabilities of SABandapos;s diversitAb™ platform by continuing advanced development of Transchromosomic goats (TcGs). This will be accomplished by producing male and female goat endogenous immunoglobulin gene knockout cell lines that contain SAB Capraandapos;s human artificial chromosome (HAC) which encod ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Improving Outcomes for Mechanically Ventilated Patients with the Digital EZ Board
SBC: VIDATAK, LLC Topic: 600DESCRIPTION provided by applicant Effective communication between patients and healthcare professionals is essential to achieve positive clinical outcomes Patients who are unable to communicate effectively e g patients with limited English proficiency LEP those who are hearing impaired aphasic or have oral tracheal intubation experience extreme frustration panic anxiety sleeplessne ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Advanced Nitric Oxide Release Bactericidal Urinary Catheters
SBC: BIOCREDE INC. Topic: 300DESCRIPTION provided by applicant In Phase I Biocrede developed a completely new urinary tract silicone Foley catheter with a andgt month shelf life made from a proprietary polymeric formulation to effectively reduce catheter associated urinary tract infections CAUTI via nitric oxide NO release for andgt weeks Key features of the new technology include catheters continuously d ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Neutralization of the Inflammasome After Spinal Cord Injury
SBC: INFLAMACORE LIMITED LIABILITY COMPANY Topic: 105DESCRIPTION provided by applicant Spinal cord injury SCI is a complex and devastating clinical condition mediated by proinflammatory cytokines that produce neuronal loss axonal destruction and demyelination during the secondary injury cascade There are currently no proven therapies targeting posttraumatic inflammation that have been shown to have clinical value We have previously shown th ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Modified HER-2 Tumor Antigens for Vaccination in Cancer
SBC: L2 DIAGNOSTICS LLC Topic: N/ADESCRIPTION (provided by applicant): Breast cancer remains one of the most insidious and difficult to treat human malignancies, affecting thousands of individuals each year. Our proposed studies are aimed at developing a novel tumor immunotherapy by using cryptic peptides of Her-2 protein and modified Her-2 peptides, both of which break immune tolerance to ?self? tumor antigens expressed on breast ...
STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health